Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the same period last year.